165 related articles for article (PubMed ID: 16829643)
1. Induction of tolerance in autoimmune diseases rather than cure of cancer by interleukin-2 therapy.
Dejaco C; Duftner C; Schirmer M
J Clin Oncol; 2006 Jul; 24(20):e34; author reply e35-6. PubMed ID: 16829643
[No Abstract] [Full Text] [Related]
2. Vitiligo in patients with melanoma: normal tissue antigens can be targets for cancer immunotherapy.
Rosenberg SA; White DE
J Immunother Emphasis Tumor Immunol; 1996 Jan; 19(1):81-4. PubMed ID: 8859727
[TBL] [Abstract][Full Text] [Related]
3. CD4+CD25highFOXP3+ regulatory T cells in peripheral blood are primarily of effector memory phenotype.
Beyer M; Schultze JL
J Clin Oncol; 2007 Jun; 25(18):2628-30; author reply 2630-2. PubMed ID: 17577047
[No Abstract] [Full Text] [Related]
4. IL-2 therapy proves durable in renal cell melanoma patients.
Oncology (Williston Park); 1991 Sep; 5(9):71. PubMed ID: 1835879
[No Abstract] [Full Text] [Related]
5. Infusion of the allogeneic cell line NK-92 in patients with advanced renal cell cancer or melanoma: a phase I trial.
Arai S; Meagher R; Swearingen M; Myint H; Rich E; Martinson J; Klingemann H
Cytotherapy; 2008; 10(6):625-32. PubMed ID: 18836917
[TBL] [Abstract][Full Text] [Related]
6. Immunotherapy With Low-Dose IL-2 in Combination With GM-CSF.
Mier JW
J Immunother; 2003; 26(2):95-6. PubMed ID: 12616100
[No Abstract] [Full Text] [Related]
7. Interleukin-2, killer cells and cancer therapy: an overview.
Parkinson DR; Lotzová E
Nat Immun Cell Growth Regul; 1990; 9(4):237-41. PubMed ID: 2215512
[No Abstract] [Full Text] [Related]
8. Cancer immunotherapy comes of age.
Rosenberg SA
Nat Clin Pract Oncol; 2005 Mar; 2(3):115. PubMed ID: 16264884
[No Abstract] [Full Text] [Related]
9. [Immunology of melanoma].
Bröcker EB; Becker JC
Hautarzt; 1995 Nov; 46(11):818-28. PubMed ID: 8641893
[No Abstract] [Full Text] [Related]
10. Immunotherapy for renal cell cancer.
Yang JC; Childs R
J Clin Oncol; 2006 Dec; 24(35):5576-83. PubMed ID: 17158543
[TBL] [Abstract][Full Text] [Related]
11. Relapse after successful treatment with immunotherapy: lessons for the future.
Fisher RI
Cancer J Sci Am; 1998; 4(2):78-9. PubMed ID: 9532407
[No Abstract] [Full Text] [Related]
12. Tumour-infiltrating lymphocytes and interleukin-2 in treatment of advanced cancer.
Kradin RL; Kurnick JT; Lazarus DS; Preffer FI; Dubinett SM; Pinto CE; Gifford J; Davidson E; Grove B; Callahan RJ
Lancet; 1989 Mar; 1(8638):577-80. PubMed ID: 2564111
[TBL] [Abstract][Full Text] [Related]
13. Active-specific immunization against melanoma: is the problem at the receiving end?
Monsurrò V; Wang E; Panelli MC; Nagorsen D; Jin P; Katia Z; Smith K; Ngalame Y; Even J; Marincola FM
Semin Cancer Biol; 2003 Dec; 13(6):473-80. PubMed ID: 15001166
[TBL] [Abstract][Full Text] [Related]
14. Interleukin-2.
Med Lett Drugs Ther; 1987 Sep; 29(749):88-9. PubMed ID: 3306301
[No Abstract] [Full Text] [Related]
15. Treatment of renal cell carcinoma and melanoma patients with immune RNA.
Pilch YH
J Exp Pathol; 1987; 3(4):501-14. PubMed ID: 2457665
[No Abstract] [Full Text] [Related]
16. Autologous large multivalent immunogen vaccine in patients with metastatic melanoma and renal cell carcinoma.
Dudek AZ; Mescher MF; Okazaki I; Math VT; Luo X; Curtsinger JM; Miller JS
Am J Clin Oncol; 2008 Apr; 31(2):173-81. PubMed ID: 18391603
[TBL] [Abstract][Full Text] [Related]
17. Immunotherapy for metastatic renal cell carcinoma.
McDermott DF; Rini BI
BJU Int; 2007 May; 99(5 Pt B):1282-8. PubMed ID: 17441925
[No Abstract] [Full Text] [Related]
18. Prolonged continuous infusion of low-dose rIL-2.
Janssen RA; Buter J; The TH; Mulder NH; de Leij L
Br J Cancer; 1994 May; 69(5):976-7. PubMed ID: 8180034
[No Abstract] [Full Text] [Related]
19. Recombinant interleukin-2 and the quest for FDA approval.
Tami JA
Clin Pharm; 1991 Feb; 10(2):141-2. PubMed ID: 2009733
[No Abstract] [Full Text] [Related]
20. Multiparametric flow cytometric analysis of signal transducer and activator of transcription 5 phosphorylation in immune cell subsets in vitro and following interleukin-2 immunotherapy.
Varker KA; Kondadasula SV; Go MR; Lesinski GB; Ghosh-Berkebile R; Lehman A; Monk JP; Olencki T; Kendra K; Carson WE
Clin Cancer Res; 2006 Oct; 12(19):5850-8. PubMed ID: 17020993
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
